Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Medicure Inc V.MPH

Alternate Symbol(s):  MCUJF

Medicure Inc. is a pharmaceutical company. It is focused on the development and commercialization of pharmaceuticals and healthcare products for patients and prescribers in the United States market. The focus of it is the marketing and distribution of AGGRASTAT (tirofiban hydrochloride) injection and ZYPITAMAG (pitavastatin) tablets in the United States, where they are sold through the Company's United States subsidiary, Medicure Pharma Inc. It also operates Marley Drug Inc. (Marley Drug), a pharmacy subsidiary servicing all 50 states, Washington D.C. and Puerto Rico. Marley Drug is committed to improving access to medication for all Americans together with exceptional customer service and free home delivery. AGGRASTAT is indicated to reduce the rate of thrombotic cardiovascular events in patients with non-ST elevation acute coronary syndrome. It also develops pyridoxal 5'-phosphate analogues (P5P Analogues), the processes for their preparation, compositions containing P5P Analogues.


TSXV:MPH - Post by User

Bullboard Posts
Comment by makinprofiton Jul 26, 2014 11:03pm
262 Views
Post# 22785106

RE:Mr. Hoe and 20 million shares

RE:Mr. Hoe and 20 million sharesThanks for that info. Have not been folowing mph much the last 3-4 years it has been a dream that became a nightmare with the failed clinical trial results. I have been plesantly surprised by the major turn of events and the bounding share price.So I dream again. With some upcoming financial results and hopefully exponential growth in hospital numbers, we could shoot to the moon. Very few shares outstanding.Aggrastat has proven to be a saviour for the company. I remember a poster,who years ago was very down on the aquisition to the rights of aggrastat.
   I hope you have more info about future plans for mph. What do you know about the plans (timeframe)for the transdermal patch.
  By the way the gentleman`s last name that you nrefer to is Hoie. A google search yielded me this info .
``Dr. Lars Henrik Høie, M.D., Ph.D.(dr. philos.) founded Nutri Pharma ASA (alternate name: Bionor Pharma ASA) in 1993 and serves as its Chairman. Dr. Høie served as the Senior Advisor of Medical and Scientific Affairs at Nutri Pharma ASA. He has more than 15 years experience in research and clinical practice of medicine. In 1986, he co-founded the Center of Heart Medicine and the Norwegian Medical Center in Oslo, and has had formal commercial agreements with Nycomed Pharma AS since 1989. Dr. Høie is the Inventor of the various products and composition patents owned by Nutri Pharma. He is published internationally and has submitted a Ph.D. thesis to Oslo University on the treatment of obesity with low calorie diets. He has been a Director of Bionor Pharma ASA since 2011. He has also conducted studies in Statistics and Epidemiology at London University. Upon completion of his Medical degree at Aarhus University in Denmark, Dr. Høie has been conducting clinical trials on obesity and metabolic syndrome.``
Bullboard Posts